Lantheus Holdings, Inc.

Final rule maintains separate payment for advanced diagnostic imaging agents and confirms PYLARIFY TruVu™ Transitional Pass-Through status through September 30, 2029; permanent HCPCS code A9613 now in effect Final rule maintains separate payment for advanced diagnostic imaging agents and confirms PYLARIFY TruVu™ Transitional Pass-Through status through September 30, 2029; permanent HCPCS code A9613 now in effect

Worldwide revenue of $389.9 million in the third quarter of 2026 GAAP fully diluted earnings per share of $0.33, compared to $0.41 in the third quarter of 2025 Adjusted fully diluted earnings per share of $1.68, compared to $1.27 in the third quarter of 2025 FDA approves TAUKLARIFY™ (florquinitau F-18 injection); an F-18-labeled tau PET imaging agent for the evaluation of adults with cognitive impairment being assessed for Alzheimer's disease FDA grants final approval for BRAVNETSA™ (lutetium Lu 177 dotatate); the only radiopharmaceutical the FDA has determined to be bioequivalent and therapeutically equivalent to LUTATHERA® for the treatment of adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) Announced on August 3, 2026 that the Company has entered into a definitive agreement to merge with Curium under which Curium US Holdings LLC will acquire all outstanding shares of the Company in an all-cash transaction that represents a total transaction value of up to approximately $8.0 billion BEDFORD, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus or the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today reported financial results for its third quarter ended September 30, 2026.

BEDFORD, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced data to be featured at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) Annual Meeting, taking place November 16 – November 19, 2026 in Boston, MA.

Shares of Lantheus Holdings, Inc. (NASDAQ: LNTH - Get Free Report) have received an average rating of "Hold" from the fourteen research firms that are covering the stock, Marketbeat.com reports. Ten research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1 year price